Evidence map›Paper›PMID 31043467›Full record

ArticleJournal of clinical microbiology2019

Performance of Three Common Hepatitis C Virus (HCV) Genotyping Assays for Identification of HCV Genotype 2/1 Chimeras.

Kai-Henrik Peiffer, Lisa Kuhnhenn, Evelyn Stelzl, Julia Dietz, Simone Susser, Andrea Oliver Tal, Fabian Finkelmeier, Eli Zuckerman, Marcus Cornberg, Mira Barak and 6 more

Open access · bronzeAbstract readComparative StudyEvaluation Study
In one paragraph

Article in Journal of clinical microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 4 countries.

Kai-Henrik PeifferMedizinische Klinik 1, Universitätsklinikum Frankfurt, Frankfurt am Main, Germany kai-henrik.peiffer@kgu.de.
Lisa KuhnhennMedizinische Klinik 1, Universitätsklinikum Frankfurt, Frankfurt am Main, Germany.
Evelyn StelzlResearch Unit Molecular Diagnostics, Diagnostic and Research Center for Molecular Biomedicine, Medical University of Graz, Graz, Austria.
Julia DietzMedizinische Klinik 1, Universitätsklinikum Frankfurt, Frankfurt am Main, Germany.
Simone SusserMedizinische Klinik 1, Universitätsklinikum Frankfurt, Frankfurt am Main, Germany.
Andrea Oliver TalMedizinische Klinik 1, Universitätsklinikum Frankfurt, Frankfurt am Main, Germany.
Fabian FinkelmeierMedizinische Klinik 1, Universitätsklinikum Frankfurt, Frankfurt am Main, Germany.
Eli ZuckermanLiver Unit, Carmel Medical Center and Rappaport Faculty of Medicine, The Technion, Haifa, Israel.
Marcus CornbergDepartment of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
Mira BarakHaifa and Western Galilee Laboratory, Clalit Health Services, Nesher, Israel.
Valeria PiazzollaLiver Unit, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy.
Alessandra MangiaLiver Unit, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy.
Stefan ZeuzemMedizinische Klinik 1, Universitätsklinikum Frankfurt, Frankfurt am Main, Germany.
Harald H KesslerResearch Unit Molecular Diagnostics, Diagnostic and Research Center for Molecular Biomedicine, Medical University of Graz, Graz, Austria.
Johannes Vermehren *Medizinische Klinik 1, Universitätsklinikum Frankfurt, Frankfurt am Main, Germany.
Christoph Sarrazin *Medizinische Klinik 1, Universitätsklinikum Frankfurt, Frankfurt am Main, Germany.
Goethe University Frankfurt · DEMedical University of Graz · ATUniversity Hospital Frankfurt · DECarmel Medical Center · ILCasa Sollievo della Sofferenza · ITClalit Health Services · ILIstituti di Ricovero e Cura a Carattere Scientifico · ITMedizinische Hochschule Hannover · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Besides seven major hepatitis C virus (HCV) genotypes (GT), a number of intergenotypic recombinant strains have been described. These so-called chimeras combine genetic characteristics of different HCV genotypes. However, correct genotype classification is important, as choice and duration of direct-acting antiviral (DAA) treatment is mainly based on the viral genotype. Therefore, misclassification of chimeras might lead to suboptimal treatment of patients infected with these strains. For example, 2k/1b chimeras are typically described as HCV genotype 2 strains by commercially available hybridization assays, but real-time PCR-based tests recognizing another HCV region might be more suitable for correct chimera detection. In this study, the analytic capacity of the hybridization-assay Versant HCV Genotype 2.0 (LiPA 2.0) and the real-time PCR-based-assays cobas HCV GT and Abbott RealTime HCV Genotype II were tested in a selected cohort of 230 patients infected with HCV genotype 1 (

Indexed as

GenotypeGenotyping TechniquesHepacivirusHepatitis CHumansMolecular Diagnostic TechniquesNucleic Acid HybridizationReagent Kits, DiagnosticReal-Time Polymerase Chain ReactionRetrospective StudiesRNA, ViralSensitivity and SpecificitySequence Analysis, DNAViral ProteinsReagent Kits, DiagnosticRNA, ViralViral Proteins2k/1bassaychimerahepatitis C virusrecombinant

Identifiers

PMID31043467
PMCPMC6595458
OpenAlexW2954997469

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.